Mirna Therapeutics, Inc. MIRN
No live quote for MIRN yet.
- Market cap
- 5.10M
- EPS (ttm)
- -1.18
- Shares out
- 2.98M
- P/E ratio
- -1.44
- Forward P/E
- -3.56
- Volume
- 40.94K
- Avg volume
- 17.60K
- Open
- 1.73
- Previous close
- 1.69
- Analysts
- Hold
- Price target
- 2.00
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -13.87M
- Total cash
- 47.72M
- Total debt
- 0
- Return on equity
- -47.28%
- Short % of float
- 0.88%
- 50-day average
- 7.79
- 200-day average
- 3.01
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.12.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2016 | H.C. Wainwright | down | — | Neutral |
| Sep 20, 2016 | Cantor Fitzgerald | down | — | Hold |
| Sep 20, 2016 | Oppenheimer | down | — | Perform |
| Sep 11, 2016 | H.C. Wainwright | init | — | Buy |
| Aug 15, 2016 | Citigroup | down | — | Neutral |
| Aug 15, 2016 | Leerink Swann | down | — | Market Perform |
About Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. does not have significant operations. It intends to identify and evaluate strategic alternatives, including a merger or sale of the company. Previously, the company was engaged in the development of microRNA-based oncology therapeutics. The company was founded in 2007 and is headquartered in Austin, Texas. Mirna Therapeutics, Inc. is a formerly subsidiary of Asuragen, Inc.
- Country
- United States
- Website
- mirnatherapeutics.com
News
Your note
Sign in to keep a note on MIRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEVA LAWRENCE M | Director | Acquisition (Non Open Market) | Oct 5, 2015 | 0 |
| BARRETT M JAMES | Beneficial Owner (10% or more) | Purchase | Oct 5, 2015 | 0 |
| BARRIS PETER J | Beneficial Owner (10% or more) | Acquisition (Non Open Market) | Oct 5, 2015 | 0 |
| BASKETT FOREST | Beneficial Owner (10% or more) | Purchase | Oct 5, 2015 | 0 |
| CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS | Beneficial Owner (10% or more) | Ownership Statement | Oct 4, 2015 | 2,395,010 |
| FLORENCE ANTHONY A. JR. | Beneficial Owner (10% or more) | Acquisition (Non Open Market) | Oct 5, 2015 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sofinnova Management VIII, L.L.C. | 14.26% | 2,974,812 | 4.55M | Jun 29, 2017 |
| NEA Management Company, LLC | 14.26% | 2,974,811 | 4.55M | Jun 29, 2017 |
| Franklin Resources, Inc | 6.64% | 1,384,073 | 2.12M | Jun 29, 2017 |
| Opaleye Management Inc. | 5.50% | 1,148,100 | 1.76M | Jun 29, 2017 |
| Vanguard Group, Inc. (The) | 0.77% | 160,006 | 244.81K | Jun 29, 2017 |
| FMR, LLC | 0.64% | 133,200 | 203.79K | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.62% | 545,947 | 1.16M | Jan 30, 2017 |
| Vanguard Total Stock Market Index Fund | 0.54% | 113,271 | 233.34K | Mar 30, 2017 |
| Fidelity Select Portfolios - Biotechnology | 0.50% | 105,000 | 151.20K | May 30, 2017 |
| Vanguard Extended Market Index Fund | 0.30% | 61,916 | 127.55K | Mar 30, 2017 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 45,000 | 92.70K | Mar 30, 2017 |
| Fidelity Advisor Biotechnology Fund | 0.14% | 28,200 | 40.61K | May 30, 2017 |